[go: up one dir, main page]

EE04951B1 - R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks - Google Patents

R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks

Info

Publication number
EE04951B1
EE04951B1 EEP200100122A EEP200100122A EE04951B1 EE 04951 B1 EE04951 B1 EE 04951B1 EE P200100122 A EEP200100122 A EE P200100122A EE P200100122 A EEP200100122 A EE P200100122A EE 04951 B1 EE04951 B1 EE 04951B1
Authority
EE
Estonia
Prior art keywords
piperidinemethanol
dimethoxyphenyl
fluorophenyl
alpha
treatment
Prior art date
Application number
EEP200100122A
Other languages
English (en)
Inventor
Mondadori Cesare
M. Sorensen Stephen
M. Hitchcock Janice
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of EE200100122A publication Critical patent/EE200100122A/et
Publication of EE04951B1 publication Critical patent/EE04951B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200100122A 1998-08-28 1999-07-29 R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks EE04951B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313598A 1998-08-28 1998-08-28
PCT/US1999/017331 WO2000012090A1 (en) 1998-08-28 1999-07-29 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

Publications (2)

Publication Number Publication Date
EE200100122A EE200100122A (et) 2002-06-17
EE04951B1 true EE04951B1 (et) 2008-02-15

Family

ID=22502745

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100122A EE04951B1 (et) 1998-08-28 1999-07-29 R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks

Country Status (32)

Country Link
EP (2) EP1105132B1 (et)
JP (1) JP2002523460A (et)
KR (3) KR100682799B1 (et)
CN (1) CN1127954C (et)
AT (1) ATE249830T1 (et)
AU (1) AU764604B2 (et)
BG (2) BG109953A (et)
BR (1) BR9913242A (et)
CA (2) CA2629396A1 (et)
CZ (1) CZ300781B6 (et)
DE (2) DE69911436T2 (et)
DK (1) DK1105132T3 (et)
EA (1) EA003791B1 (et)
EE (1) EE04951B1 (et)
ES (1) ES2204146T3 (et)
HK (1) HK1040907B (et)
HR (2) HRP20010140A2 (et)
HU (1) HUP0202145A3 (et)
ID (1) ID29601A (et)
IL (2) IL141603A0 (et)
ME (1) MEP20308A (et)
MX (1) MXPA01002026A (et)
NO (2) NO20010984L (et)
NZ (1) NZ510083A (et)
PL (1) PL195022B1 (et)
PT (1) PT1105132E (et)
SK (1) SK284858B6 (et)
TR (1) TR200100670T2 (et)
TW (1) TWI233802B (et)
UA (1) UA74773C2 (et)
WO (1) WO2000012090A1 (et)
ZA (1) ZA200101466B (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
ATE353693T1 (de) 2002-07-19 2007-03-15 Biovitrum Ab Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
EP0325063B1 (en) * 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
JP2869512B2 (ja) 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド （＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
JPH05134149A (ja) * 1991-11-08 1993-05-28 Nippondenso Co Ltd 光半導体モジユール
US5618824A (en) 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US9702597B1 (en) 2016-02-18 2017-07-11 King Fahd University Of Petroleum And Minerals System and method for preventing absorbent crystallization in a continuously operating solar-powered absorption cooling system with hybrid storage

Also Published As

Publication number Publication date
EA003791B1 (ru) 2003-10-30
HRP20010140A2 (en) 2002-02-28
CZ300781B6 (cs) 2009-08-12
KR100735513B1 (ko) 2007-07-06
DK1105132T3 (da) 2003-11-24
BR9913242A (pt) 2001-05-15
SK2692001A3 (en) 2001-07-10
BG65416B1 (bg) 2008-07-31
CN1315861A (zh) 2001-10-03
DE69941134D1 (de) 2009-08-27
EP1362589A1 (en) 2003-11-19
DE69911436D1 (de) 2003-10-23
PL346342A1 (en) 2002-02-11
TWI233802B (en) 2005-06-11
IL141603A (en) 2006-08-20
KR20010073026A (ko) 2001-07-31
SK284858B6 (sk) 2006-01-05
HRP20080389A2 (hr) 2008-11-30
CN1127954C (zh) 2003-11-19
NO20010984D0 (no) 2001-02-27
TR200100670T2 (tr) 2001-06-21
NO20091111L (no) 2001-04-25
PT1105132E (pt) 2004-02-27
KR100682799B1 (ko) 2007-02-15
KR100764532B1 (ko) 2007-10-09
MEP20308A (en) 2010-06-10
ES2204146T3 (es) 2004-04-16
NO20010984L (no) 2001-04-25
EP1105132B1 (en) 2003-09-17
JP2002523460A (ja) 2002-07-30
MXPA01002026A (es) 2003-03-27
ATE249830T1 (de) 2003-10-15
KR20060057029A (ko) 2006-05-25
HUP0202145A3 (en) 2003-02-28
EA200100201A1 (ru) 2001-08-27
ZA200101466B (en) 2002-05-21
CZ2001726A3 (en) 2001-06-13
IL141603A0 (en) 2002-03-10
CA2341891A1 (en) 2000-03-09
BG109953A (en) 2007-12-28
UA74773C2 (en) 2006-02-15
PL195022B1 (pl) 2007-08-31
CA2629396A1 (en) 2000-03-09
EP1105132A1 (en) 2001-06-13
HUP0202145A2 (hu) 2003-01-28
KR20060023197A (ko) 2006-03-13
NZ510083A (en) 2003-08-29
WO2000012090A1 (en) 2000-03-09
BG105289A (en) 2001-11-30
AU764604B2 (en) 2003-08-21
AU5135999A (en) 2000-03-21
HK1040907B (zh) 2004-04-02
CA2341891C (en) 2009-05-12
ID29601A (id) 2001-09-06
HK1040907A1 (en) 2002-06-28
EE200100122A (et) 2002-06-17
EP1362589B1 (en) 2009-07-15
DE69911436T2 (de) 2004-07-01

Similar Documents

Publication Publication Date Title
DE69814394D1 (de) Verwendung von levobupivacain
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
MY111623A (en) Neuroprotective compounds
BR9708109A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinametanol no tratamento de distúrbios depressivos e distúrbios bipolares
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
EE200100122A (et) R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks
BR9708037A (pt) Método para o tratamento de abuso de substância
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
YU15301A (sh) PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20100729